Table 1 Patient characteristics first hospitalized for AMI with and without DPP-4 inhibitor
Characteristics | Control group (NÂ =Â 2672) | DPP-4 inhibitor group (NÂ =Â 2672) | P value |
|---|---|---|---|
Gender | |||
 Female | 1098 (41.09%) | 1098 (41.09%) | 1 |
 Male | 1574 (58.91%) | 1574 (58.91%) |  |
Age | |||
 Age <65 | 1064 (39.82%) | 1059 (39.63%) | 0.8468 |
 65 ≤ age < 75 | 707 (26.46%) | 725 (27.13%) |  |
 Age ≥75 | 901 (33.72%) | 888 (33.23%) |  |
Comorbidities | |||
 Hypertension | 2016 (75.45%) | 2005 (75.04%) | 0.7274 |
 Dyslipidemia | 1996 (74.7%) | 1996 (74.7%) | 1 |
 Peripheral vascular disease | 144 (5.39%) | 144 (5.39%) | 1 |
 Heart failure | 971 (36.34%) | 994 (37.2%) | 0.5141 |
 End stage renal disease | 187 (7%) | 187 (7%) | 1 |
 COPD | 231 (8.65%) | 234 (8.76%) | 0.8842 |
 Cerebrovascular accident | 789 (29.53%) | 796 (29.79%) | 0.8339 |
Operations | |||
 Percutaneous coronary intervention | 1699 (63.59%) | 1699 (63.59%) | 1 |
 Coronary artery bypass graft | 260 (9.73%) | 297 (11.12%) | 0.0976 |
 IABP | 240 (8.98%) | 248 (9.28%) | 0.704 |
Medication | |||
 Aspirin | 2330 (87.2%) | 2440 (91.32%) | <0.0001 |
 Clopidogrel | 2350 (87.95%) | 2454 (91.84%) | <0.0001 |
 Any anti-platelet drug | 2513 (94.05%) | 2596 (97.16%) | <0.0001 |
 ACEI or ARB | 1743 (65.23%) | 2007 (75.11%) | <0.0001 |
 Statin | 1616 (60.48%) | 1780 (66.62%) | <0.0001 |
 β-Blocker | 1587 (59.39%) | 1884 (70.51%) | <0.0001 |
 CCB | 980 (36.68%) | 1145 (42.85%) | <0.0001 |
 Heparin or low molecular weight heparin | 2174 (81.36%) | 2266 (84.81%) | 0.0008 |
 Spironolactone | 468 (17.51%) | 615 (23.02%) | <0.0001 |
 Nitrate | 2245 (84.02%) | 2366 (88.55%) | <0.0001 |
 Nicorandil | 284 (10.63%) | 401 (15.01%) | <0.0001 |
 α-Glucosidase | 197 (7.37%) | 602 (22.53%) | <0.0001 |
 Glinides | 311 (11.64%) | 644 (24.1%) | <0.0001 |
 Metformin | 781 (29.23%) | 1168 (43.71%) | <0.0001 |
 Sulfonylureas | 778 (29.12%) | 1420 (53.14%) | <0.0001 |